ARTICLE | Clinical News
Mepact regulatory update
July 12, 2004 7:00 AM UTC
The EMEA granted Orphan Medicinal Product designation to Mepact macrophage activator to treat osteosarcoma. Mepact has completed Phase III trials and has Orphan Drug designation in the U.S. ...